Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

648469 Troglitazone - CAS 97322-87-7 - Calbiochem

A α-tocopherol (vitamin E) moiety containing thiazolidinedione class of insulin-sensitizer that acts as an activator of peroxisome proliferator-activated receptors γ (PPARγ).

Troglitazone - CAS 97322-87-7 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
Primary Target: Peroxisome proliferator-activated receptors γ (PPARγ)
648469
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
97322-87-7C₂₄H₂₇NO₅S

Products

RéférenceConditionnement Qté
648469-5MG Ampoule plast. 5 mg
Description
OverviewA α-tocopherol (vitamin E) moiety containing thiazolidinedione class of insulin-sensitizer that acts as an activator of peroxisome proliferator-activated receptors γ (PPARγ). Also exhibits anti-proliferative and anti-inflammatory properties. Shown to induce cell cycle arrest and apoptosis in human hepatoma cells. Inhibits vascular smooth muscle cell (VSMC) migration by rapidly activating MEK/ERK pathway leading to the induction of c-fos and Ets-1 expression. Blocks PDGF-induced cell proliferation of pancreatic stellate and accelerates p21Cip1 turnover by inhibiting PKCδ signaling in VSMCs. Exerts positive inotropic effect via Ca2+ sensitization in the sarcoplasmic reticulum and inhibits Na+/H+ exchange activity and proliferation of macrovascular endothelial cells.
Catalogue Number648469
Brand Family Calbiochem®
References
ReferencesMasamune, A., et al. 2002. J. Biol. Chem. 277, 141.
Boyault, S., et al. 2001. FEBS Lett. 501, 24.
de Dios, S.T., et al. 2001. J. Diabetes Complications 15, 120.
Furuse, Y., et al. 2001. Br. J. Pharmacol. 133, 1307.
Ghanim, H., et al. 2001. J. Clin. Endocrinol. Metab. 86, 1306.
Goetze, S., et al. 2001. J. Cardiovasc. Pharmacol. 38, 909.
Koga, H., et al. 2001. Hepatology 33, 1087.
Rosen, E.D. and Spiegelman, B.M., 2001. J. Biol. Chem. 276, 37731.
Subbaramaiah, K., et al. 2001. J. Biol. Chem. 276, 12440.
Takashima, T., et al. 2001. Int. J. Oncol. 19, 465.
Takeda, K., et al. 2001. J. Biol. Chem. 276, 48950.
Tanaka, T., et al. 2001. Cancer Res. 61, 2424.
Wakino, S., et al. 2001. J. Biol. Chem. 276, 47650.
Product Information
CAS number97322-87-7
ATP CompetitiveN
FormWhite to yellow solid
Hill FormulaC₂₄H₂₇NO₅S
Chemical formulaC₂₄H₂₇NO₅S
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetPeroxisome proliferator-activated receptors γ (PPARγ)
Purity≥98% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSXJ5813130
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C. Ethanol stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
648469-5MG 04055977262469

Documentation

Troglitazone - CAS 97322-87-7 - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Troglitazone - CAS 97322-87-7 - Calbiochem Certificats d'analyse

TitreNuméro de lot
648469

Références bibliographiques

Aperçu de la référence bibliographique
Masamune, A., et al. 2002. J. Biol. Chem. 277, 141.
Boyault, S., et al. 2001. FEBS Lett. 501, 24.
de Dios, S.T., et al. 2001. J. Diabetes Complications 15, 120.
Furuse, Y., et al. 2001. Br. J. Pharmacol. 133, 1307.
Ghanim, H., et al. 2001. J. Clin. Endocrinol. Metab. 86, 1306.
Goetze, S., et al. 2001. J. Cardiovasc. Pharmacol. 38, 909.
Koga, H., et al. 2001. Hepatology 33, 1087.
Rosen, E.D. and Spiegelman, B.M., 2001. J. Biol. Chem. 276, 37731.
Subbaramaiah, K., et al. 2001. J. Biol. Chem. 276, 12440.
Takashima, T., et al. 2001. Int. J. Oncol. 19, 465.
Takeda, K., et al. 2001. J. Biol. Chem. 276, 48950.
Tanaka, T., et al. 2001. Cancer Res. 61, 2424.
Wakino, S., et al. 2001. J. Biol. Chem. 276, 47650.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision23-March-2018 JSW
DescriptionA α-tocopherol (vitamin E) moiety containing thiazolidinedione class of insulin-sensitizer that acts as an activator of peroxisome proliferator-activated receptors γ (PPARγ). Also exhibits anti-proliferative and anti-inflammatory properties. Shown to induce cell cycle arrest and apoptosis in human hepatoma cells. Inhibits vascular smooth muscle cell (VSMCs) migration by rapidly activating MEK/ERK pathway leading to the induction of c-fos and Ets-1 expression. Blocks PDGF-induced cell proliferation of pancreatic stellate and accelerates p21cip1 turnover by inhibiting PKCδ signaling in VSMCs. Exerts positive inotropic effect via Ca2+ sensitization in sarcoplasmic reticulum and inhibits Na+/H+ change activity.
FormWhite to yellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number97322-87-7
RTECSXJ5813130
Chemical formulaC₂₄H₂₇NO₅S
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (10 mg/ml) or ethanol (5 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C. Ethanol stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesMasamune, A., et al. 2002. J. Biol. Chem. 277, 141.
Boyault, S., et al. 2001. FEBS Lett. 501, 24.
de Dios, S.T., et al. 2001. J. Diabetes Complications 15, 120.
Furuse, Y., et al. 2001. Br. J. Pharmacol. 133, 1307.
Ghanim, H., et al. 2001. J. Clin. Endocrinol. Metab. 86, 1306.
Goetze, S., et al. 2001. J. Cardiovasc. Pharmacol. 38, 909.
Koga, H., et al. 2001. Hepatology 33, 1087.
Rosen, E.D. and Spiegelman, B.M., 2001. J. Biol. Chem. 276, 37731.
Subbaramaiah, K., et al. 2001. J. Biol. Chem. 276, 12440.
Takashima, T., et al. 2001. Int. J. Oncol. 19, 465.
Takeda, K., et al. 2001. J. Biol. Chem. 276, 48950.
Tanaka, T., et al. 2001. Cancer Res. 61, 2424.
Wakino, S., et al. 2001. J. Biol. Chem. 276, 47650.